Naratriptan Al

Naratriptan, the active ingredient in Naratriptan Al, is a Triptan (selective 5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adult patients.

GNH USA supplies Naratriptan Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan is used in the management of migraine, a vascular headache disorder.

- Migraine without aura: provides rapid relief of headache pain and associated symptoms during an acute attack. - Migraine with aura: reduces the severity of headache and associated nausea when taken at onset. - Acute migraine attacks: aborts the migraine episode and improves functional ability.

Naratriptan may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Dry mouth: reduced salivation causing throat discomfort. - Paresthesia: tingling or numbness in the extremities.

Serious or Rare Side Effects: - Chest pain or tightness: may indicate coronary vasospasm. - Severe hypertension: sudden increase in blood pressure. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with serotonergic agents. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Ischemic cardiac events: myocardial infarction or angina in susceptible individuals.

Before prescribing Naratriptan, consider the following precautions to ensure safe use.

- Cardiovascular disease: evaluate risk of coronary artery disease before use. - History of stroke or transient ischemic attack: avoid due to potential cerebrovascular effects. - Concomitant serotonergic medications: monitor for signs of serotonin syndrome. - Pregnancy: safety not established; use only if benefit outweighs risk. - Elderly patients: start with the lowest effective dose and monitor closely. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Naratriptan can interact with other medicines; notable interactions are categorized by clinical significance.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - SSRIs, SNRIs, or other serotonergic agents: may precipitate serotonin syndrome. - Ergot alkaloids: combined vasoconstriction can cause serious cardiovascular events. - Other triptans: additive vasoconstrictive effect increases risk of ischemia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase naratriptan plasma levels. - CYP2D6 inhibitors (e.g., fluoxetine): may modestly raise exposure, requiring observation.